Caren Deardorf
CIK 1871152 · Chief Commercial Officer · last filed 2025-06-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$561.9K
Companies
2
Total Filings
14
Lifetime Open-Market Net
-$42.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRNX | Director | 16,300 | $34.47 | $561.9K | $0 | 6 | 2025-06-13 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Chief Commercial Officer | 19,762 | $11.19 | $221.2K | -$42.0K | 8 | 2022-12-02 |
Recent Filings · Page 2 of 2
14 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-02-17 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-09-20 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Sell (S) | −6,238 | -$42.0K | EDGAR |
| 2021-09-16 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | +20,000 | $0 | EDGAR |
| 2021-07-08 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 11–14 of 14
Prev
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.